Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
- Author:
Soongu KWAK
1
;
Han Mo YANG
Author Information
- Publication Type:Review
- Keywords: Anticoagulants; Atrial fibrillation; Non-vitamin K antagonist oral anticoagulant; Percutaneous coronary intervention
- MeSH: Anticoagulants; Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Percutaneous Coronary Intervention; Stents
- From:Journal of Lipid and Atherosclerosis 2019;8(1):8-14
- CountryRepublic of Korea
- Language:English
- Abstract: Choosing antithrombotic regimens for patients with atrial fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with stent placement is challenging. Until recently, the guidelines recommended warfarin-based triple therapy, which causes frequent major bleeding events in up to 12% of patients during the first year of treatment. The WOEST trial, however, revealed that dual therapy, by without aspirin, resulted in significantly lower bleeding risks with similar thromboembolic events to triple therapy. Subsequently, efforts to seek the optimal dual therapy regimens, especially with the combination of a non-vitamin K antagonist oral anticoagulant (NOAC), were initiated. This review highlights the evidence for dual therapy using an NOAC for patients with AF who underwent PCI, with an emphasis on reduced bleeding risk.
